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Abstract
Single doses of resveratrol have previously been shown to increase cerebral blood flow (CBF) with no clear effect on cognitive function or
mood in healthy adults. Chronic resveratrol consumption may increase the poor bioavailability of resveratrol or otherwise potentiate its
psychological effects. In this randomised, double-blind, placebo-controlled, parallel-groups study, a total of sixty adults aged between 18 and
30 years received either placebo or resveratrol for 28 d. On the 1st and 28th day of treatment, the performance of cognitively demanding tasks
(serial subtractions, rapid visual information processing and 3-Back) (n 41 complete data sets) was assessed, alongside blood pressure (n 26)
and acute (near-IR spectroscopy (NIRS)) and chronic (transcranial Doppler) measures of CBF (n 46). Subjective mood, sleep quality and
health questionnaires were completed at weekly intervals (n 53/54). The results showed that the cognitive effects of resveratrol on day 1 were
restricted to more accurate but slower serial subtraction task performance. The only cognitive finding on day 28 was a beneficial effect of
resveratrol on the accuracy of the 3-Back task before treatment consumption. Subjective ratings of ‘fatigue’ were significantly lower across the
entire 28 d in the resveratrol condition. Resveratrol also resulted in modulation of CBF parameters on day 1, as assessed by NIRS, and
significantly increased diastolic blood pressure on day 28. Levels of resveratrol metabolites were significantly higher both before and after the
day’s treatment on day 28, in comparison with day 1. These results confirm the acute CBF effects of resveratrol and the lack of interpretable
cognitive effects.
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Resveratrol (3,4′,5 trihydroxystilbene) is a polyphenolic sec-
ondary metabolite produced within plants in response to a
range of environmental stressors(1). Previous investigations in
young, healthy humans have demonstrated significantly
increased cerebral blood flow (CBF) after acute resveratrol
supplementation(2), which is probably mediated by the ability
of resveratrol to modulate nitric oxide synthesis(3). In line with
this, oral consumption has been shown to enhance
endothelium-dependent relaxation in rats(4,5), and to improve
flow-mediated dilatation in overweight/obese humans(6). An
increase in blood-borne neural metabolic substrates such as
oxygen(7) and glucose(8) has been shown to enhance aspects of
cognitive performance in healthy, young humans. However, to
date, there is no evidence that cognitive function is modulated
during acute, resveratrol-mediated increases in CBF.
One potential explanation for this lack of cognitive effects is the
rapid metabolism and poor bioavailability of oral resveratrol(9),
which might reduce its potential bioactivity. Pharmacokinetic
studies have demonstrated plasma Cmax levels of resveratrol
metabolites between 0·9 and 3·7 µM following a single oral dose of
500mg of resveratrol(10), with levels of the parent compound at
trace or undetectable concentrations(2,10–13) after acute, bolus
supplementation. Conversely, results from three preclinical che-
mopreventive efficacy papers suggest that repeated low daily
doses of resveratrol (up to 2mg/kg) are sufficient to produce peak
plasma concentrations of aglycone resveratrol of up to 2 µM,
potentially exerting beneficial chemopreventive effects(14) possibly
as a result of a cumulative increase in plasma levels of resveratrol.
Thus, the current study investigated the effects of 28-d sup-
plementation with 500mg of resveratrol in healthy adults, with
* Corresponding author: E. L. Wightman, email emma.l.wightman@northumbria.ac.uk
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the hypothesis being that daily consumption of this polyphenol,
over an extended period, may increase bioavailability in terms
of plasma levels and may potentiate any effects on cognitive
performance and CBF. In the current study, continuous-wave
near-IR spectroscopy (CW-NIRS) was used to monitor acute
changes in CBF in the prefrontal cortex during the performance
of cognitive tasks that activate this brain region. This technique
was combined with transcranial Doppler (TCD) sonography,
applied to the middle cerebral artery (MCA), which provides a
measure of acute and chronic changes in global CBF velocity
(CBFV) and which has been converged successfully with NIRS
previously(15). Resveratrol has previously been shown to inter-
act with a number of diffuse, health-related parameters such as
antioxidant and anti-inflammatory status(16,17), monoamine
oxidase-A and B (MAO-A/B) activity(18) and peroxisome
proliferator-activated receptor gamma coactivator 1-alpha
PGC-1α(19) production. Hence, the current study also assessed
health, mood and sleep parameters via questionnaires.
Methods
Participants
All participants reported themselves to be in good health and
free from illicit drugs, alcohol, prescription medication and her-
bal extracts/food supplements at each assessment. Participants
confirmed that they would also abstain from the latter for the
duration of the study and that any changes in medication or
health status would be reported to the researcher when they
occurred. Participants who had suffered a head injury, neurolo-
gical disorder or neuro-developmental disorder were excluded
from participation, as were those who did not have English as
their first language, or had any relevant food allergies or intol-
erances, digestive problems, smoked tobacco, drank excessive
amounts of caffeine (more than 600mg/d as assessed by a caf-
feine consumption questionnaire), took illicit social drugs, were
pregnant, seeking to become so or were breast-feeding.
The study received ethical approval from the Northumbria
University Psychology Department (within the Faculty of Health
and Life Sciences) ethics committee (reference: SUB16_EW_1010;
date approved 11 November 2010) and was conducted according
to the Declaration of Helsinki (1964). All participants gave their
written informed consent before their inclusion in the study.
See Table 1 for participant composition (broken down per
analysis).
Treatments
Over the course of this 28-d supplementation study, participants
received either 500 mg of pure trans-resveratrol (TransmaxTM
by BiotiviaTM with a guaranteed purity of 98 %, also containing
10 mg of piperine/ capsule) or an inert placebo (methyl cellu-
lose) once daily, with the treatment allocation dictated by Latin
square. Participants were instructed to consume their daily
capsule in the morning and preferably with breakfast.
Participants consumed their first and last capsule of treatment
during the two laboratory visits and were instructed to self-
supplement every day in the interim. Participants kept a treat-
ment log during this time, noting down the time of capsule
consumption every day. A treatment pot containing thirty-two
capsules was given to each participant at the end of visit 1,
which was enough for 28 d of supplementation plus extra in
case of loss, continued supplementation because of unforeseen
circumstances and to verify compliance.
All treatments were administered in identical green vegetar-
ian capsules with the BiotiviaTM logo and presented in identical
white treatment pots with only the participant number to
identify them. All treatments were produced by BiotiviaTM,
prepared by the lead investigator and coded by a third party
who had no further involvement in any aspect of the study. No
member of the investigational team was aware of the contents
of the capsules until a blind-data review was completed.
Measures of cerebral blood flow (CBF)
Two complementary techniques were used as follows.
Acute changes in CBF-NIRS: NIRS is non-invasive brain
imaging technique predicated on the absorption by oxygenated
HB (oxy-Hb) and deoxygenated Hb (deoxy-Hb) of differing
wavelengths of IR light, introduced through the intact scalp/
skull. CW-NIRS can be used to assess acute changes in local
CBF, as indexed by concentration changes in total Hb during a
Table 1. Participant composition*
Measure (number of participants) Female/male (n) Mean age (years) Age range (years) Right handed/left handed (n) Placebo/resveratrol (n)
Overall recruited (n 60) 51/9 20·52 18–29 53/7 30/30
Cognitive performance (n 41) 36/5 20·00 18–27 35/6 19/22
NIRS (n 46) 39/7 20·45 18–29 39/7 24/22
TCD (n 46) 40/6 20·08 18–29 40/6 21/25
Blood pressure (n 24) 21/3 20·75 18–29 21/3 15/9
GHQ (n 53) 45/8 20·17 18–29 46/7 28/25
POMS (n 54) 46/8 20·07 18–29 47/7 28/26
PSQI (n 53) 45/8 20·15 18–29 47/6 28/25
Food consumption (n 55) 47/8 20·15 18–29 48/7 29/26
Treatment guess (n 57) 49/8 20·25 18–29 50/7 28/29
NIRS, near-IR spectroscopy; TCD, transcranial Doppler; GHQ, General Health Questionnaire; POMS, Profile of Mood States; PSQI, Pittsburgh Sleep Quality Index.
* In all, sixty participants were originally recruited to take part in all aspects of assessments apart from the blood pressure measurement, which utilised only thirty participants
because of the potential disruption this may have caused to NIRS measurement. Reasons for excluding data from analyses include: technical problems with equipment (affecting
aspects of twelve cognitive performance data sets, fourteen NIRS, fourteen TCD recordings (namely not being able to locate a consistent, 5-min, blood flow trace in the latter and
data which were outside of the calculated standard deviations of this cohort, and may suggest an ill-fitting headband, with regards NIRS) and six blood pressure readings) and
participants not complying with proper completion of measures/omitting to respond (affecting aspects of seven cognitive performance data sets, seven responses from the GHQ,
six from the POMS, seven from the PSQI, five from the food consumption questionnaire and three from the treatment guess response).
1428 E. L. Wightman et al.
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core . U
niversity of N
ottingham
, on 19 Jun 2020 at 11:53:46 , subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114515003037
single continuous recording session; see Kennedy et al.(2) for a
full description of the methods used here. Given that CW-NIRS
generates concentration change data that is intrinsically
baseline-adjusted to the concentration immediately before the
first data point in the recording session, it cannot be used to
quantify gross changes in CBF parameters that take place
between two separate recording sessions. In this instance, the
change from baseline data generated by the NIRS system was
subjected to a second baseline adjustment by creating ‘change
from baseline’ data with respect to the 10 min of NIRS data
collected immediately before the treatment; this provided a
more accurate baseline measure of immediately pre-treatment
NIRS parameters. All subsequent NIRS data were collapsed into
2-min epochs (twenty resting-period epochs spanning 0–40min
and twenty task-period epochs spanning 40–80 min).
Chronic changes in CBF-TCD: given the inability of
CW-NIRS to measure chronic changes in CBF parameters, a
second measure of CBF was also used. TCD sonography is a
non-invasive method of measuring CBFV through the basal
intracerebral vessels through the intact skull(20), and it was used
at pre- and post-dose time points on day 1 and day 28. Pulses of
ultrasound penetrate the skull at a number of ‘acoustic
windows’, which include temporal, orbital, foraminal and
submandibular, insonating vessels at particular depths, with the
returning ‘echo’ displayed as a Doppler waveform(21). The
mean velocity, peak systolic velocity, diastolic velocity and
pulsatility index (all centimetre per second) of the insonated
vessel are provided, indicating the speed of the flow of blood
and the variability of blood velocity.
TCD has been used to investigate blood flow abnormalities in
a number of haematological, for example, stroke risk in sickle
cell patients(22), and vascular, for example, cerebrovascular
reactivity in degenerative and vascular dementia(23), disorders,
as well as investigating the relationship between brain activity
(in response to cognitive tasks) and blood flow velocity in
healthy participants(24) and the CBFV response to pharmaco-
logical interventions, for example, caffeine(25), and drugs, for
example, in cocaine abusers(26).
In the current study, CBFV was measured with participants
sitting in a reclined position in a quiet room. A trans-temporal
acoustic window was used for assessment of the right MCA using
pulsed TCD (Digi-LiteTM; Rimed) with a 2-MHz probe held in
place by a light, mounted head frame. This device provides
mean velocity, peak systolic velocity, diastolic velocity and
pulsatility index information every 30 sec, equating to approxi-
mately 10 values across the 5-min recording used here, for each
of the four aforementioned variables. These were averaged to
give 1 value for that time point (before and after dose on day 1
and before and after dose on day 28) for statistical analysis.
Cognitive tasks
The computerised battery of cognitive tasks (which all, to a
greater or lesser extent, activate the prefrontal cortex: serial
subtractions(27); rapid visual information processing (RVIP)(28);
3-Back(29)) were delivered on a laptop using the Computerised
Mental Performance Assessment System (COMPASS, University
of Northumbria) software, and they comprised
serial subtractions (2 min each of serial 7, 13 and 17 s)
RVIP (2 min)
Both the serial subtraction and RVIP task are described in
detail in Kennedy et al.(2).
3-Back: the 3-Back version of this task was used in this
paradigm, and it required participants to indicate whether the
letter presented on screen was also present three letters back in
the letter sequence. Participants must respond by pressing the
‘yes’ or ‘no’ button on the response box, to each letter, as
quickly as they can. This task lasts for 2 min, and it is scored for
accuracy and reaction time.
Questionnaires
Food consumption questionnaire. A non-validated food
consumption questionnaire was used to collect information on
the general diet of participants (e.g. ‘How many portions of fruit
and vegetables did you eat on an average day in the past
week?’) and specifically polyphenol/resveratrol consumption
(e.g. ‘In the entire previous week, on how many occasions have
you eaten a portion of berries or grapes?’). The questionnaire
consisted of thirteen questions, with several questions also
relating to compliance (e.g. ‘Was treatment consumed with
breakfast and/or before 9:30 am every day in the past week?’)
and medication (‘Have you consumed any medication in the
past week? If so, please state the medication, dose, when taken
and for what reason’). This researcher-created questionnaire
has no reliability/sensitivity measures, and it was used solely as
a tool to detect any gross changes in the consumption patterns
of participants, which might affect outcome measures. The
researcher noted no salient dietary or medication changes
across the study for any of the participants.
General Health Questionnaire. The General Health
Questionnaire (GHQ)(30) used in the current study was the
twenty-eight-item scaled version, which assesses somatic
symptoms, anxiety and insomnia, social dysfunction and severe
depression. The twenty-eight items are scored from 0 to 3, with
participants indicating the frequency or extent to which they
have experienced a number of issues, such as ‘Have you
recently been having hot or cold spells?’, in the previous week.
The items combine to assess the four aforementioned
sub-scales, and the total possible score (when these four
sub-scales are collated) ranges from 0 to 84, with higher scores
representing more negative symptoms.
Profile of Mood States. The Profile of Mood States (POMS) is a
well-validated questionnaire of mood states and their fluctua-
tions both in the clinical and research settings(31). Participants
rated sixty-five adjectives (e.g. unhappy, considerate), in terms
of how much they had felt each one in the past week, using a
five-point scale from ‘not at all’ to ‘extremely’. Scores from these
sixty-five items (which includes seven dummy adjectives) are
combined to give six global scores of ‘tension’, ‘depression’,
‘anger’, ‘fatigue’, ‘confusion’ and ‘vigour’. A total mood
Chronic effects of resveratrol in humans 1429
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disturbance score can also be calculated by adding the scores
from the first five of these global scores and subtracting ‘vigour’.
Pittsburgh Sleep Quality Inventory. The Pittsburgh Sleep
Quality Inventory (PSQI) is a well-validated subjective measure
of the quality and pattern of sleep(32). The current study tailored
this questionnaire to assess sleep during the past ‘week’ rather
than ‘monthly’ as per the original. The PSQI assesses seven
factors – subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleep
medication and daytime dysfunction – via questions regarding
sleep timings and zero to three-point scales in which
participants rate whether they have experienced a number of
issues (e.g. ‘During the past week, how often have you had
trouble sleeping because you have had bad dreams?’) from ‘not
during the past week’ to ‘3 or more times in the past week’. A
global sleep score is created by totalling the seven subfactor
scores, with higher scores indicating poorer sleep quality.
Treatment guess
During the day 28 visit, participants were asked to guess which
treatment they thought they had been taking for the duration of
the study and to explain any reasons for that guess.
Procedure
This investigation required participants to attend the laboratory
for an initial training/screening session and then on two
separate occasions, 28 d apart, for laboratory-based testing
sessions. Participants were required to supplement themselves
with one capsule per d in the interim.
Upon arrival at both day 1 and day 28, laboratory visit par-
ticipants completed four questionnaires: a food consumption
questionnaire; the GHQ; POMS; and the PSQI. All ques-
tionnaires were answered in relation to the previous 7 d and
completed every 7 d during the supplementation period. After
filling in the questionnaires, participants then gave a blood
pressure (BP) reading or an intravenous blood sample (fifteen
participants provided blood samples; see below for more
information and the demographics of the seven participants
from the resveratrol condition entered into the analysis), which
was immediately followed by a 5-min rest. A 5-min recording of
cerebral perfusion in the MCA was then taken with TCD. The
NIRS headband was then positioned onto the forehead of the
participant to monitor CBF in the prefrontal cortex throughout
the session. Once a reliable trace was identified, participants
commenced 20 min (×2 repetitions of the battery) of baseline
cognitive tasks. The first of these repetitions acted as a
‘refresher’, attenuating any practice effects, and the second was
used to create change from baseline data for the analysis of
cognitive outcome data. A 10-min rest period then followed,
with NIRS data averaged across this period and used as an
accurate, immediately pre-treatment baseline for the calculation
of change from baseline data for the post-treatment periods.
During this 10-min resting period, participants watched a non-
arousing DVD. Participants then consumed the first day’s
treatment and continued to watch the DVD for a further 40-min
absorption period. After this period, a BP reading was taken in
those who did not provide a blood sample previously and
40 min of post-dose tasks commenced. After completion of the
task, a further BP reading was taken from the relevant partici-
pants, followed by a short break before the second TCD
recording was conducted. After the TCD recording, participants
were either free to leave the laboratory or provided a final
blood sample if they were part of the aforementioned
sub-section of participants. The timelines and running order of
the testing sessions are shown in Fig. 1.
Bioavailability assessment
Participants. Complete sample sets comprising all four time
points were obtained from fifteen participants (eight from pla-
cebo and seven from resveratrol; ten females and five males;
mean age 19·87 years; range 18–25 years). All participants were
N
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ent
Fig. 1. Upon arrival, participants completed four questionnaires (a food
consumption questionnaire, the General Health Questionnaire, Profile of Mood
States and the Pittsburgh Sleep Quality Index), which they answered in relation
to the previous 7 d and completed every 7 d during the supplementation period.
Participants then gave a blood pressure (BP) reading or an intravenous blood
sample, which was immediately followed by a 5-min rest. A 5-min recording of
cerebral perfusion in the middle cerebral artery was then taken with the
transcranial Doppler (TCD). The near-IR spectroscopy (NIRS) headband was
then positioned, and 20min of baseline tasks commenced. A 10-min rest then
followed, during which participants watched a non-arousing DVD. Participants
then consumed their treatment capsule and continued to watch the DVD for a
further 40-min absorption period. A BP reading was then taken from a sub-
sample of participants and 36min of post-dose tasks commenced. The NIRS
headband was removed and a further BP reading taken, followed by a short
break, before the second TCD recording was conducted. Following the TCD
recording, the aforementioned sub-section of participants provided a blood
sample and left the laboratory. RVIP, rapid visual information processing.
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asked, at the beginning of the study, if they would provide
blood samples as part of the investigation: the above fifteen
participants represent those who agreed to this aspect of the
study and for whom all four samples could be collected in full.
The seven resveratrol participants included in the analysis
comprised six females and one male, with a mean age of 19·43
years, ranging from 18 to 21 years.
Venous blood samples were collected before consuming the
day’s treatment, and 110 min post dose in this sub-sample of
participants using 4·7-ml monovettes (containing lithium heparin)
(Sarstedt AG & Co.). Samples were centrifuged at 2500 rpm for
15min at 20ºC to yield plasma, which was then stored at –80°C
until analysis.
The preparation of samples and LC-MS analysis are as per a
previous study conducted by this laboratory(33).
Statistics
The analyses of TCD, plasma, questionnaire, behavioural and
treatment guess data were conducted with IBM SPSS Statistics
19.0 for Windows (SPSS Inc.). NIRS data were analysed with
Minitab 16 for Windows (Minitab Inc.).
Questionnaire data analysis. Questionnaire data (GHQ,
POMS and PSQI) for each of the four post-dose weekly com-
pletions were analysed as change from baseline (the ques-
tionnaire scores obtained on day 1 before treatment) for each
individual variable/sub-component by a mixed (day (×4): 7, 14,
21, 28, by treatment (×2): 500 mg resveratrol and placebo)
ANOVA with Bonferroni-corrected post hoc Student’s t tests
conducted if a significant main and/or interaction effect was
evinced here.
Treatment guess analysis. Treatment guess data were ana-
lysed by χ2 test.
Transcranial Doppler. The raw data for each of the four TCD
variables (mean velocity, peak systolic velocity, diastolic
velocity and pulsatility index) were analysed by a mixed
(treatment (×2): 500 mg resveratrol and placebo, by time (×4):
baseline day 1, post-dose day 1, pre-dose day 28 and post-dose
day 28) ANOVA.
Plasma analysis. The raw data for each of the four forms of
plasma resveratrol (resveratrol-3-sulphate, resveratrol-4'-O-glu-
curonide, resveratrol-3'-O-glucuronide and ‘total metabolites’;
which is the sum of the three metabolites) were analysed via
ANOVA with time as a factor (×4: baseline day 1, post-dose
day 1, pre-dose day 28 and post-dose day 28).
Cognitive task data and blood pressure analysis. The cog-
nitive task and BP measures produce data that can be analysed
to assess both acute (potential treatment effects within day 1),
pure-chronic (chronic treatment-related effects that have taken
place across the 28-d supplementation period but before taking
the day 28 treatment) and superimposed acute/chronic (the
difference in ‘acute’ effects between day 1 and day 28) effects of
resveratrol. To adequately analyse the ‘acute’, ‘pure chronic’
and ‘superimposed acute/chronic’ effects of the treatments, two
separate ANOVA were conducted:
1. Pure chronic effects
To ascertain whether any pure chronic effects of resveratrol
supplementation had taken place, pre-dose data on day 28
were converted to change from day 1 pre-dose baseline and
analysed via one-way ANOVA to compare performance
between treatments.
2. Acute, chronic and superimposed effects
To ascertain whether any acute and/or superimposed
chronic effects of resveratrol supplementation had taken
place, data were converted to change from baseline with
respect to the pre-treatment scores on the first day of treat-
ment (day 1) and analysed via a repeated measures ANOVA
(treatment (resveratrol/placebo,× repetition (×4 for cogni-
tive data and ×2 for BP), by day (day 1/28)).
Both ANOVA were used in order to tease apart acute effects
restricted to day 1 (treatment×day interactions with significant
effects restricted to day 1), acute effects across both day 1 and
day 28 (main effect of treatment and/or a treatment× repetition
interaction) and a superimposed acute/chronic effect (treat-
ment×day interaction with significant effects restricted to day 28
(interpreted with reference to the pure chronic ANOVA results)).
If any such main and/or interaction effects were observed, then
Bonferroni-corrected post hoc Student’s t tests were conducted to
assess where these differences lie. This analysis plan has proven
sensitivity in detecting the acute and chronic effects of ginseng in
healthy, human participants previously(34).
Near-IR spectroscopy analysis. NIRS data were converted to
‘change from baseline’ (calculated from the 10-min pre-treat-
ment resting period) and averaged across 2-min epochs during
the 40-min ‘rest/absorption’ and 40-min cognitive task perfor-
mance period. ANOVA (treatment group× 2-min epoch×day)
was conducted on these data, with planned comparisons of
data from each epoch being made between placebo and
500 mg of resveratrol (resulting in forty planned comparisons
for oxy-HB, deoxy-Hb and total-Hb) using t tests calculated
with the mean squares error from the ANOVA(35). A significant
result on this ANOVA was not used as a prerequisite for car-
rying out and interpreting the planned comparisons, and it is
therefore not presented here. However, in order to reduce the
potential for type I errors, all planned comparisons were Bon-
ferroni corrected, and only those planned comparisons asso-
ciated with a consistent pattern of significant effects are
interpreted and reported herein.
Results
Compliance
Potential compliance ranged from 0 to 114% (the upper limit
reflecting thirty-two capsules consumed over 28 d). Average
compliance was 101 %, with a range of 78·5–114·3%. Data from
one participant with 78·5 % compliance (who provided blood
samples in the placebo condition only) were excluded from
Chronic effects of resveratrol in humans 1431
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analysis, because they were below a pre-set level of 80%, making
average compliance 101·4% with a range of 92·9–114·3 %.
Treatment guess
χ2 test revealed no significant difference between treatment
guesses in the two treatment groups: χ2= 0·766; df= 1; P= 381.
Near-IR spectroscopy parameters
Total Hb. Planned comparisons revealed that, on day 1, levels
of total-Hb were significantly higher after resveratrol, compared
with placebo, during the 2-min epochs spanning 35–38min
post dose (35/36 min (P= 0·003), 37/38 min (P= 0·008)) in the
absorption period and the epochs spanning 75–78min (75/
76 min (P= 0·008), 77/78 min (P= 0·005)) of the post-dose task
period. No significant differences were found between resver-
atrol and placebo on day 28.
Oxygenated Hb. Planned comparisons revealed that, on day 1,
levels of oxy-Hb were significantly higher in the resveratrol
condition, compared with placebo, during the 2-min epochs
commencing 23 (P= 0·002), 27 (P= 0·005), 33 (P= 0·002), 35
(P= 0·001) and 37 (P= 0·009) min post dose in the absorption
period and the epochs spanning 41–44 (41/42 (P= 0·006),
43/44 (P= 0·001)), 53–54 (P= 0·001), 61–68 (P= 0·0008, 0·001,
0·007 and 0·001, respectively), 71–72 (P= 0·003), 75–78 (75/76
(P= 0·0002) and 77/78 (P= 0·0002)) min of the post-dose task
period. No significant differences were found between resver-
atrol and placebo on day 28.
Deoxygenated Hb. Planned comparisons revealed that, on
day 1, levels of deoxy-Hb were significantly higher in the placebo
condition, compared with resveratrol, during the 2-min epochs
commencing 27 (P= 0·001), 29 (P=0·006) and 35 (P= 0·003)min
post-treatment in the absorption period and the epochs com-
mencing 43 min (P=0·004), and spanning 51–54 min (51/52 min
(P=0·0002), 53/54 min (P=0·004)), and those spanning 61–72
min (61/62 min (P=0·001), 63/64 min (P=0·003), 65/66 min
(P=0·0005), 67/68 min (P=0·002), 69/70 min (P= 0·004), 71/72
min (P= 0·0008), respectively) and those spanning 75–80 min (75/
76 min (P= 0·001), 77/78 min (P=0·003), 79/80 min (P=0·004),
respectively)min of the post-dose task period. No significant dif-
ferences were found between resveratrol and placebo on day 28.
Mean total-, oxy- and deoxy-Hb levels for placebo and resver-
atrol, across day 1 and day 28, are shown in Fig. 2.
Transcranial Doppler parameters
No significant acute chronic or gross chronic effects were
observed with any of the four TCD parameters (Mean velocity,
peak systolic velocity, diastolic velocity and pulsatility index).
Cognitive task performance
1. Pure chronic ANOVAThe results of the ANOVA on day 28
pre-dose data (converted to change from day 1 baseline)
comparing performance between 500 mg of resveratrol and
placebo demonstrated a significant effect of treatment for
the 3-Back task in terms of the percentage of correct
responses (F1,40= 8·60; P= 0·006), with better performance
in the resveratrol condition as compared with placebo.
2. Acute, chronic and superimposed ANOVA
The results of the treatment× repetition×day ANOVA are as
follows. Note that, for brevity, only those significant main and/or
interaction effects involving treatment are described here, but see
online Supplementary Materials for all ANOVA F and P value tables.
7s incorrect. Analysis revealed a main effect of treatment
(F1,39= 6·40; P= 0·016) (with the mean for number of serial 7s
incorrect responses for placebo, overall, higher than the mean
for 500mg resveratrol) and a day× repetition× treatment
interaction (F3,117= 0·260; P= 0·034). Post hoc comparisons
(Bonferroni corrected) revealed a significant difference on day
1 at repetition 4 (P= 0·005) and trends for differences on day 1
at repetition 2 (P= 0·073) and on day 28 at repetition 3
(P= 0·070). The mean number of incorrect responses was lower
in the 500-mg resveratrol condition in all three cases.
17s correct. The ANOVA revealed an interaction between
day× treatment× repetition (F3,117= 3·45; P= 0·019). Post hoc
comparisons revealed significant differences on day 28 at
repetition 1 and repetition 3 (both P= 0·04), with the mean
number of serial 17s correct completions being higher in the
placebo condition in both cases.
17s incorrect. The ANOVA showed a main effect of treatment
(F1,39= 5·79; P= 0·021) (with the mean number of 17s sub-
traction incorrect responses, overall, being higher in the pla-
cebo condition as compared with 500 mg of resveratrol). An
interaction between repetition× treatment (F3,117= 3·55;
P= 0·017) was also observed. With regard to the repetition×
treatment interaction, post hoc comparisons revealed only one
significant comparison between treatments at the fourth repe-
tition on day 28. Here, the mean number of incorrect responses
was higher (P= 0·003) in the placebo condition.
General health
There were no significant treatment-related differences on the
GHQ or its subcomponents.
Sleep
There were no significant treatment-related differences on the
PSQI or its subcomponents.
Mood
A significant treatment effect was observed for the ‘fatigue’
measure alone (F1,52= 9·37; P= 0·003), which was derived from
the POMS questionnaire. Further analysis with Bonferroni-
corrected post hoc Student’s t tests demonstrated that subjective
ratings of fatigue were significantly lower for resveratrol on
day 7 (P= 0·04), day 21 (P= 0·013) and day 28 (P= 0·001). A
move towards a trend was also evinced for day 14 (P= 0·097).
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See online Supplementary Materials for average weekly ratings
on POMS questionnaire and ANOVA F and P value tables.
Blood pressure
1. Pure chronic ANOVA
The results of the ANOVA on day 28 pre-dose BP
measurements (converted to change from day 1 baseline)
comparing readings between 500mg of resveratrol and
placebo demonstrated only a significant effect for diastolic
BP (F1,28= 5·86; P= 0·022), with levels being higher in the
resveratrol condition.
2. Acute, sub-chronic and superimposed ANOVA
No significant effects were observed for systolic BP or heart rate.
For diastolic BP, a significant interaction between treatment×day
was evinced (F1,22=6·61; P= 0·017), which revealed only one
significant comparison in the placebo condition between day 1
and day 28 at the 40-min post-dose measurement (P=0·46). Here
the mean was higher overall on day 28 compared with day 1.
See online Supplementary Materials for BP values and
ANOVA F and P value tables.
Plasma analysis (total metabolite levels)
6A significant effect of time was observed (F1·35,8·10= 7·50;
P= 0·02) for levels of total resveratrol metabolites (the sum of
resveratrol 3-O-sulphate and resveratrol-4'- and 3'-O-glucur-
onides), with pair wise comparisons revealing that day 1 post-
dose levels were higher than day 1 baseline (P= 0·023), that day
28 pre-dose levels were higher than day 1 baseline (P= 0·033)
and that day 28 post-dose levels were higher than both day 1
baseline (P= 0·003) and day 28 pre-dose levels (P= 0·005). All
three metabolites followed this same pattern of significance, and
thus, for brevity, only total metabolite levels are reported here.
No resveratrol (in any form) was found in baseline samples
on day 1, indicating that all volunteers did not consume
resveratrol-containing products before the study. No aglycone
resveratrol was quantifiable in plasma at any time point, on
either day. Resveratrol 3-O-sulphate was the predominant
metabolite in all volunteers, contributing 73–77 % of total
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Fig. 2. Concentration changes from baseline in levels of (top) total Hb (Total-Hb), (middle) oxygenated Hb (Oxy-Hb) and (bottom) deoxygenated Hb (Deoxy-Hb)
averaged across two-min epochs during a 40-min absorption period and subsequent 40min of cognitive task performance following placebo or 500mg of resveratrol
on day 1 and day 28 (n 46). , Placebo; , 500 mg of resveratrol. Values are means, with standard errors represented by vertical bars. Significance planned
comparisons (Bonferroni corrected) between resveratrol and placebo of data from each 2-min epoch: * P< 0·05 and ** P< 0·01.
Chronic effects of resveratrol in humans 1433
D
ow
nloaded from
 https://w
w
w
.cam
bridge.org/core . U
niversity of N
ottingham
, on 19 Jun 2020 at 11:53:46 , subject to the C
am
bridge C
ore term
s of use, available at https://w
w
w
.cam
bridge.org/core/term
s . https://doi.org/10.1017/S0007114515003037
metabolites. The 4'- and 3'-O-glucuronide forms evinced
roughly equal contributions to the remaining metabolites in
circulation.
Mean plasma concentration values (µM) for resveratrol
metabolites at baseline and post-dose (110 min after adminis-
tration) on day 1 and, after daily 500-mg consumption, on day
28 are shown in Fig. 3.
Discussion
In summary, the results here show that although a single dose
of 500mg of trans-resveratrol can modulate CBF parameters in
the frontal cortex in a pattern consistent with increased blood
flow, supplementation for 28 d does not result in any clear
improvements in cognitive function, despite an increase in
plasma metabolite levels. However, there was evidence of
significantly reduced fatigue and higher diastolic BP following
extended supplementation. No modulation of subjective sleep
quality, health or chronic CBF was observed.
The chronic 28-d dosing paradigm used in the current paper
was designed to address the potential ineffectiveness of
resveratrol at eliciting cognitive performance effects after acute,
bolus supplementation(2,33). The hypothesis was that chronic
consumption of resveratrol might increase exposure to resver-
atrol – a polyphenol with known low bioavailability following
acute administration(9). This increased exposure may be
expected to enhance the biological activity of resveratrol,
specifically, of importance here, those with direct and/or
indirect effects on cognitive function. However, analysis
demonstrated that the only cognitive task measure to evince a
pure chronic effect (derived by the comparison of changes in
performance between resveratrol and placebo between day 1
baseline and day 28 before dose) was N-Back % correct: that is,
after 28 d of supplementation, participants in the 500-mg
resveratrol condition completed significantly more correct
3-Back responses before taking their day’s treatment, as
compared with placebo. No effects on this measure were
observed after consumption of treatment on day 1 or day 28,
nor were any effects observed on the other accuracy sub-
measure assessed here. The results of acute and chronic/
superimposed analysis revealed that, on day 28, participants in
the resveratrol condition performed slower, achieving less
correct responses on the serial 17 subtractions task. However,
on day 1 and day 28, participants in the same condition also
performed more accurately (less incorrect responses) on the
serial 7 and serial 17 subtraction tasks. Although these results
suggest a speed accuracy trade-off, closer inspection of these
significant main effects highlights an inconsistent and difficult-
to-interpret pattern, with the effects on the serial 7 task
restricted to the fourth task battery repetition on day 1 only and
the first, third and fourth repetitions, on day 28, for the effects
on the serial 17 subtraction task, where both higher and lower
performance was seen in the resveratrol condition. Because of
the lack of any clear pattern of results in both the acute and
chronic effects of resveratrol on cognition here (and indeed the
previous two studies assessing the effects of resveratrol on
cognitive function), it is important to regard these results with
caution. It may be that the relatively small sample here is
masking a real effect, or a clearer effect, of resveratrol or it may
be that a number of type I errors have inflated expectations.
Nevertheless, only a tightly controlled, cross-over study with
greater power would be able to address this issue.
The current study demonstrates that 500 mg of trans-resver-
atrol is able to augment the CBF response to cognitive task
demands, relative to placebo, after acute, oral administration to
healthy human participants. This acute augmentation mani-
fested in small, significantly higher levels of total-Hb, indicative
of increased CBF, at the ends of the absorption- and post-dose
task periods and a consistent pattern of significantly higher
levels of oxy-Hb across some of the absorption- and post-dose
task periods following the first dose of resveratrol on day 1.
Levels of deoxy-Hb were also significantly lower in the
resveratrol condition, as compared with placebo. This latter
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Fig. 3. Plasma concentrations of resveratrol metabolites( , total metabolites; , sulphate; , 4’ glucuronide; , 3’ glucuronide) at baseline
and post-dose (110 min post-administration of 500 mg trans-resveratrol) on day 1 and day 28. Values are means (n 7), with standard errors represented by
vertical bars.
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finding is directly opposite to that reported previously(2,33), and
it is contrary to the hypothesis that resveratrol would facilitate
increased oxygen extraction because of its reported effects on
oxidative phosphorylation(36). No clear reason for this anom-
alous finding can be offered at present, but it may be notable
that although the previous two aforementioned resveratrol/
NIRS studies by this laboratory were cross-over studies the
current study is the first to use a between-subjects design, and
this may introduce an unanticipated degree of variability in CBF
parameters. In contrast to day 1, the consumption of the
resveratrol treatment on day 28 was not found to have an acute
effect on any of the CBF parameters. As noted above, CW-NIRS
generates concentration change, rather than quantitative data,
and therefore it only provides a measure of acute changes in
haemodynamics during each discrete recording session. It
therefore provides no direct measure of any changes that have
taken place between recording sessions, in this case as a con-
sequence of chronic resveratrol supplementation. The lack of
an effect here may then reflect several distinct possibilities. It
may, of course, reflect a simple attenuation of the acute effects
seen following the first dose of resveratrol on day 1. However, it
could equally reflect either the raised levels of resveratrol
metabolites seen before treatment on day 28, which may have
precluded a further acute effect of an additional dose on day 28,
or it may indicate that a gross (undetected) change in CBF
parameters had already taken place, attenuating the possibility
of any additional acute effects of the day 28 treatment.
In the current study, TCD was also incorporated to provide a
measure of chronic CBF. This technique provides an absolute
quantitative measure of CBF (in this case as indexed by CBFV in
the right MCA), which was intended to elucidate any gross
chronic changes in CBF as a consequence of resveratrol
supplementation. No significant changes in CBFV were
observed with TCD, suggesting a simple absence of modulation
of CBF by resveratrol. However, this interpretation should be
tempered by several considerations. The first is that the
recording period was much shorter (at 5 min) than for NIRS,
and it was undertaken entirely at rest, with no data collected
during the period of task performance, during which resveratrol
has been shown to have its most pronounced effects. Second,
although the NIRS was used to measure local changes in CBF in
the upper layers of the frontal cortex during tasks that activate
this brain area, the right MCA supplies the entire right side of the
cortex. Given this, any vasodilatory effects restricted to the
locality of neural activity (in this case the prefrontal cortex) may
have been swamped in the gross blood flow. Potential reasons
for a lack of significant CBFV changes include the relatively
short recording period with the TCD: 5 min, yielding only two
measurements per minute, which may simply be to narrow a
window to detect effects. The TCD recording periods were also
conducted during times of minimal cognitive demand (pre and
post the cognitive task periods) and, as such, metabolic
substrate demands would have been less during these periods
and an increase in the haemodynamic response unnecessary.
Ideally, the TCD and NIRS would both have been used to
record concomitantly throughout the absorption and cognitive
task periods. Unfortunately, because of the physical constraints
of the equipment used here, this was not possible.
The current study does, however, report vascular effects of
resveratrol in the periphery on day 28, with the analysis of pure
chronic effects (derived by comparing change from day 1
baseline BP measurements between resveratrol and placebo to
pre-treatment on day 28) demonstrating higher diastolic BP in
resveratrol-supplemented participants. No pre-treatment
baseline differences in BP readings nor acute effects of treat-
ment within day 1 or day 28 were observed. This finding is
intuitively unexpected, as resveratrol has previously been
shown to be a vasodilator(6,37) – a phenomenon associated with
lowered BP. Whether resveratrol can act as a vasoconstrictor
is, at present, unknown, but it may be noteworthy that struc-
turally similar polyphenols, such as the tea polyphenol
epigallocatechin-3-gallate (EGCG), can act both as both
vasodilators and vasoconstrictors depending on the dose and
the time of assessment(38). EGCG has also been investigated
with regard to its cognitive and CBF effects in humans, with a
single dose of 135 mg leading to a significant reduction in CBF
as compared with placebo, which might indeed be suggestive
of vasoconstriction.
No significant differences between treatments, or within-
treatment changes, were observed with subjective perceptions
of general health (as assessed by the GHQ) or sleep
(as assessed by the PSQI). With regard to subjective perceptions
of mood, the only variable on the POMS questionnaire that
evinced any significant difference was ‘fatigue’, which remained
significantly lower across the entire 28-d period in the resver-
atrol condition, as compared with placebo. Little research exists
regarding the effects of polyphenols on mood, but this
anti-fatigue effect may find an explanation in in vitro and ani-
mal work, which reports the ability of resveratrol to inhibit
MAO-A/B activity. This inhibition was reported to lead to an
increase in monoamine neurotransmitter concentrations,
namely 5-hydroxytryptophan (5-HT), noradrenaline and dopa-
mine, with a concomitant improvement in mood, which was
similar to that seen with imipramine and fluoxetine in mice(18).
Interestingly, quercetin, another red wine polyphenol, also
shows anti-fatigue activity through increased energy expendi-
ture and endurance capacity in mice(39,40) and power output in
elite male cyclists when part of a cocktail of supplemented
compounds(41). Mechanisms include increased blood flow
because of vasorelaxation(42) and oxygenation, with Davis
et al.(40) also reporting SIRT-mediated increases in mitochon-
drial gene expression in brain and skeletal muscles. Both
mechanisms are shared with resveratrol(36,42) and could explain
the increased energy levels seen here. It is worth noting here
that, although there was no statistically significant difference in
baseline (before dose on day 1) levels of fatigue between
resveratrol and placebo participants, the baseline values were
nevertheless numerically higher in the former group (8·04
compared with 5·54, respectively), which might suggest that this
effect represents a return to normal levels for the resveratrol
group following an unusually high baseline.
Analysis of the plasma samples, taken from a sub-sample of
seven participants from the resveratrol condition on day 1,
demonstrated increases in acute resveratrol metabolite levels
post dose very similar to those seen in a previous study
conducted by this laboratory(2). Pre-dose levels of metabolites on
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day 28 were also significantly higher than pre-dose levels on day
1, suggesting that chronic consumption results in an accumulation
of resveratrol metabolites in plasma. They subsequently increased
following the day 28 treatment, and again ended at a significantly
higher level than that post dose on day 1. Pre- and post-dose
levels of resveratrol on day 28 were significantly higher than
baseline levels on day 1 and, within day 28, post-dose levels were
significantly higher than pre-dose levels. Taken together, these
findings suggest (hence their presence before treatment admin-
istration on day 28) that this may amplify the increase following
acute administration (hence numerically higher levels at day 28
post dose compared with day 1 post dose). The fact that the day 1
baseline mean levels were 0 does render this comparison statis-
tically problematic. However, disregarding statistical significance,
the fact that metabolites were present on day 28 (considering
that levels were 0 at baseline on day 1) is indicative that an
increase in plasma levels of resveratrol had taken place. This
novel finding of accumulating levels of resveratrol metabolites
as a consequence of chronic administration certainly warrants
further investigation with larger samples, as previous acute dose
research does not suggest that plasma metabolites should still
be present beyond 24 h(9), or certainly not at the pre-dose levels
seen here on day 28(10). It may be possible that these effects are
the result of some other, unknown, factor/s – for instance, the
consumption by participants of more resveratrol-containing
products or an additional resveratrol capsule before attending
the laboratory on day 28. However, this seems unlikely, and is
argued against by the participants’ treatment diaries and a
capsule count.
The methodology of the current study had a number of
strengths and limitations. The nature of the paradigm, namely the
time frame involved and the use of equipment that dictates indi-
vidual testing (i.e. the NIRS and TCD), necessarily means that the
sample size is somewhat restricted for outcome measures such as
cognitive performance, which ideally require a larger sample than
the physiological measures. In this study, the issue was exacer-
bated by the loss of a number of sets of data (due largely to an
equipment failure), which reduced the number of cognitive per-
formance data sets. This renders interpretation of the cognitive
data more difficult, but an argued strength of this paper is the
caution with which the authors have regarded such data. Another
limitation relates to the equipment utilised here to measure CBF.
As noted above, CW-NIRS only generates acute concentration
change data, and therefore the question that it was used to
address on day 28 of the current study was ‘Are the acute hae-
modynamic effects of the single dose of resveratrol taken on day
28 the same, or different, to those seen following the first dose
taken on day 1?’. The results showed that there were no acute
effects on day 28, and thus they were different. However, the
difficulty in interpreting this finding further is that this could reflect
an attenuation of the acute effects over time, but it could equally
be the result either of the raised levels of resveratrol metabolites
already seen before taking the day 28 treatment, or indeed
unmeasured chronic effects on CBF. To address the last of these
points, TCD was incorporated as a measure of chronic changes of
absolute CBFV, but this measure showed no effect, although again
this could be due to methodological issues (including measuring
at rest, rather than during task performance, and the diffuse rather
than local nature of the measurement). It would therefore be
advantageous to revisit the question of the chronic effects of
resveratrol on CBF using the more recently introduced ‘quantita-
tive’ NIRS, which, as the name suggests, generates quantitative,
rather than concentration change, data. In terms of strengths, the
current paper incorporated a range of methodologies in order to
answer the hitherto unaddressed question as to whether resver-
atrol can engender chronic cognitive effects. This is also the first
paper to show that repeated consumption of resveratrol can lead
to cumulative plasma levels at a dose that is recommended by
many over-the-counter resveratrol products.
In conclusion, the current study reports that chronic, 28-d
supplementation of 500mg of trans-resveratrol results in
significantly reduced fatigue and higher diastolic BP, but it does
not modulate sleep, health or chronic CBF. The single, chronic,
cognitive effect evinced by resveratrol and the confusing
pattern of acute effects should be treated with caution. This
study is the first to suggest that chronic resveratrol consumption
could result in cumulative plasma levels in healthy humans after
oral administration.
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